Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yoshiaki Amino
Observed names:
Y Amino,
Y. Amino,
YOSHIAKI AMINO
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
Kanazawa University,
Kanazawa University Hospital,
Fukui-ken Saiseikai Hospital,
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0002-3242-0662
Observed ORCID:
0000-0002-3242-0662
OpenAlex ID:
A5023713698
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
2020
·
Takehiro Tozuka
, Satoru Kitazono
, et al.
·
BMC Cancer
·
47
PDF
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
2019
·
TSUKASA HASEGAWA
, NORIKO YANAGITANI
, et al.
·
Anticancer Research
·
41
PDF
Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment
2020
·
Takehiro Tozuka
, Satoru Kitazono
, et al.
·
Lung Cancer
·
38
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer
2022
·
Siew-Kee Low
, Ryo Ariyasu
, et al.
·
Translational Lung Cancer Research
·
36
PDF
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
2020
·
Ryo Ariyasu
, Ken Uchibori
, et al.
·
Thoracic Cancer
·
29
PDF
Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens
2025
·
Mayu Sugai
, Yoshiaki Amino
, et al.
·
Lung Cancer
·
21
PDF
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
2021
·
TAKEHIRO TOZUKA
, NORIKO YANAGITANI
, et al.
·
Anticancer Research
·
20
PDF
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
2023
·
Ryo Ariyasu
, Sho Kakuto
, et al.
·
JTO Clinical and Research Reports
·
19
PDF
Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
2020
·
Takehiro Tozuka
, Satoru Kitazono
, et al.
·
Thoracic Cancer
·
19
PDF
Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
2024
·
Keiki Miyadera
, Sho Kakuto
, et al.
·
Cancers
·
17
PDF
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
2020
·
TSUKASA HASEGAWA
, NORIKO YANAGITANI
, et al.
·
In Vivo
·
15
PDF
Advances in the treatment of postoperative recurrence of non–small cell lung cancer and their impact on survival in Asian patients
2022
·
Kohei Hashimoto
, Ryo Ariyasu
, et al.
·
Journal of Thoracic and Cardiovascular Surgery
·
10
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC
2019
·
Yoshiaki Amino
, Satoru Kitazono
, et al.
·
International Journal of Clinical Oncology
·
10
Minimal Change Disease Associated With Durvalumab
2021
·
Masataro G. Toda
, Kentaro Fujii
, et al.
·
Kidney International Reports
·
8
PDF
A case of EGFR mutation‐positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR‐TKI treatment
2019
·
Hideharu Kimura
, Yoshiaki Amino
, et al.
·
癌症:英文版
·
7
PDF
Efficacy of osimertinib in patients with EGFR ‐mutation positive non‐small cell lung cancer with malignant pleural effusion
2024
·
Ayu Kiritani
, Yoshiaki Amino
, et al.
·
Thoracic Cancer
·
6
PDF
Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
2021
·
Hiroaki Sakamoto
, Noriko Yanagitani
, et al.
·
Cancer Reports
·
6
PDF
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
2021
·
Ken Uchibori
, Natsuki Takano
, et al.
·
Thoracic Cancer
·
6
Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients
2020
·
Takehiro Tozuka
, Noriko Yanagitani
, et al.
·
Cancer Treatment and Research Communications
·
6
PDF
Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers
2024
·
Takahiro Akita
, Ryo Ariyasu
, et al.
·
Thoracic Cancer
·
4
PDF
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients
2023
·
Takehiro Tozuka
, Noriko Yanagitani
, et al.
·
Investigational New Drugs
·
4
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy
2022
·
Shinsuke Ogusu
, Ryo Ariyasu
, et al.
·
Investigational New Drugs
·
3
A case of gingival cancer with pulmonary metastases that developed complete atrioventricular block and ventricular fibrillation as a result of myocardial metastases
2016
·
Taro Yoneda
, Kazumasa Kase
, et al.
·
Clinical Case Reports
·
3
PDF
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
2023
·
Yoshiaki Amino
, Siew‐Kee Low
, et al.
·
Thoracic Cancer
·
2
A retrospective analysis of the efficacy of immune checkpoint inhibitors (ICIs) to advanced non-small cell cancer (NSCLC) patients (pts) with central nerve system (CNS) metastasis.
2018
·
Takashi Sone
, Kazuo Kasahara
, et al.
·
Journal of Clinical Oncology
·
2
Show more works
View as search
Works count:
36
Citation count:
385
H-index:
11
I10-index:
13
Year
Topic
Type